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David F. Meoli, MD, PHD,* Kailasnath Purushothaman, PHD,† Luiz Belardinelli, MD,‡
Albert J. Sinusas, MD*†
New Haven, Connecticut; and Palo Alto, California
O B J E C T I V E S The purpose of this study was to compare a selective A2A adenosine receptor agonist
(regadenoson) with adenosine in clinically relevant canine models with regard to effects on hemodynamics
and thallium-201 (201Tl) and technetium-99m (99mTc)-sestaMIBI biodistribution and kinetics.
B A C KG ROUND The clinical application of vasodilator stress for perfusion imaging requires
consideration of the effects of these vasodilating agents on systemic hemodynamics, coronary ﬂow, and
radiotracer uptake and clearance kinetics.
METHOD S Sequential imaging and arterial blood sampling was performed on control, anesthetized
closed-chest canines (n  7) to evaluate radiotracer biodistribution and kinetics after either a bolus
administration of regadenoson (2.5 g/kg) or 4.5-min infusion of adenosine (280 g/kg). The effects of
regadenoson on coronary ﬂow and myocardial radiotracer uptake were then evaluated in an open-chest
canine model of a critical stenosis (n  7). Results from ex vivo single-photon emission computed
tomography were compared with tissue well-counting.
R E S U L T S The use of regadenoson compared favorably with adenosine in regard to the duration and
magnitude of the hemodynamic effects and the effect on 201Tl and 99mTc-sestaMIBI biodistribution and
kinetics. The arterial blood clearance half-time was signiﬁcantly faster for 99mTc-sestaMIBI (regadenoson:
1.4  0.03 min; adenosine: 1.5  0.08 min) than for 201Tl (regadenoson: 2.5  0.16 min, p  0.01;
adenosine: 2.7  0.04 min, p  0.01) for both vasodilator stressors. The relative microsphere ﬂow deﬁcit
(0.34  0.02%) during regadenoson stress was signiﬁcantly greater than the relative perfusion defect
with 99mTc-sestaMIBI (0.69 0.03%, p 0.001) or 201Tl (0.53 0.02%, p 0.001), although 201Tl tracked
the ﬂow deﬁcit within the ischemic region better than 99mTc-sestaMIBI. The perfusion defect score was
larger with 201Tl (22  2.8% left ventricular) than with 99mTc-sestaMIBI (17  1.7% left ventricular, p 
0.05) on ex vivo single-photon emission computed tomography images.
CONC L U S I O N S The bolus administration of regadenoson produced a hyperemic response compa-
rable to a standard infusion of adenosine. The biodistribution and clearance of both 201Tl and 99mTc-sestaMIBI
during regadenoson were similar to adenosine vasodilation. Ex vivo perfusion images under the most ideal
conditions permitted detection of a critical stenosis, although 201Tl offered signiﬁcant advantages over
99mTc-sestaMIBI for perfusion imaging during regadenoson vasodilator stress. (J Am Coll Cardiol Img 2009;
2:1198–208) © 2009 by the American College of Cardiology Foundation
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1199yocardial stress-rest perfusion imaging
is used to detect coronary artery dis-
ease. Thallium-201 (201Tl)-labeled and
technetium-99m (99mTc)-labeled tracers,
uch as 99mTc-sestaMIBI (99mTc-MIBI), are used
nterchangeably for the detection of coronary artery
isease. However, there are substantial differences
n myocardial uptake, clearance kinetics, and bio-
istribution among the 99mTc-labeled tracers and
01Tl (1,2), which should be considered in myocar-
ial perfusion imaging (MPI).
See page 1209
The accuracy of MPI is dependent on the biodis-
ribution of tracers in organs adjacent to the heart (i.e.,
ungs, liver) and affects the optimal timing of MPI (3).
atients with a critical coronary stenosis who are
nable to exercise are injected during pharmacological
asodilator stress to mimic alterations in coronary flow
ssociated with exercise stress. The level or type of
tress can affect the biodistribution (4–8). The bio-
istribution of 99mTc-MIBI is altered by exercise or
harmacological stress, suggesting that the kinetics
lso are influenced (3). The uptake of 99mTc-MIBI
lateaus at high flows during adenosine vasodilator
tress, potentially underestimating myocardial perfu-
ion defect size (9).
Adenosine used for stress MPI causes systemic
ascular and hemodynamic side effects, possibly
ltering the biodistribution of radiotracers (9). Most
dverse effects can be attributed to A1, A2B, and A3
denosine receptor stimulation (10). Selective A2A
denosine receptor agonists may reduce unwanted
ffects but may alter radiotracer kinetics. Regade-
oson (CVT-3146, CV Therapeutics, Inc., a sub-
idiary of Gilead, Foster City, California), an A2A
gonist, is a potent vasodilator with a short duration
f action and minimal hemodynamic effects
10,11). Recent clinical trials (12–16) have estab-
ished regadenoson as a vasodilator for MPI.
Studies in conscious dogs and humans demon-
trated that the dose and rate of regadenoson
dministration affects hemodynamics (11) and cor-
nary flow (10,17,18). Differential effects of rega-
enoson on renal and splanchnic flow may affect the
iodistribution and clearance of radiotracers, having
n impact on the efficacy of the vasodilator MPI.
Regadenoson duration of action and differential
ffects on flow (coronary and systemic) compared with
denosine may result in favorable tracer kinetics for
PI. To determine whether regadenoson results in
avorable conditions for vasodilator MPI, we evaluated she uptake, biodistribution, and clearance of 201Tl and
9mTc-MIBI during vasodilation with regadenoson
nd adenosine in chronic, closed-chest canine models.
o establish the linearity of radiotracer uptake during
egadenoson stress, we used acute open-chest canine
odels with a critical stenosis.
E T H O D S
urgical preparation. Fasting adult mongrel dogs (23
0.9 kg) were anesthetized with intravenous sodium
hiamylal (20 mg/kg). Animals were intubated and
entilated with a mixture of halothane (0.5% to 1.5%),
itrous oxide and oxygen (N2O:O2  3:1). An elec-
rocardiogram (ECG) lead was used for heart rate
HR) and rhythm monitoring. The protocol was
pproved by Yale Institutional Animal Care
nd Use Committee in compliance with
uiding principles of the American Physio-
ogic Society on research animal use.
HRONIC MODEL. Venous access was es-
ablished for administration of radiotracer
nd regadenoson or adenosine. A femoral
rtery was cannulated for blood sampling
nd hemodynamic monitoring. To deter-
ine radiotracer kinetics and biodistribu-
ion, sequential imaging was performed in
losed-chest (n  7) dogs under light anes-
hesia and physiological conditions with
onitoring.
CUTE MODEL. To determine the effects of
egadenoson on coronary flow and myocar-
ial radiotracer uptake, an open-chest canine
reparation (n  7) with a critical stenosis
as used. A left lateral thoracotomy was
erformed and the heart suspended in a
ericardial cradle. The proximal left ante-
ior descending (LAD) and circumflex (LCX) ar-
eries were dissected for placement of flow probes
Transonics Systems Inc., Ithaca, New York). A
roximal critical LCX stenosis was created by the
se of a hydraulic occluder and adjusted to blunt
eactive hyperemia to a transient 10-s total coronary
cclusion without impairing resting flow. Central
emperature, HR, aortic pressure (AoP), and coro-
ary flows were recorded. Radiolabeled micro-
pheres (15-m diameter; Sc-46, Nb-95, Ru-103,
nd Sn-113) were injected in the left atrium.
rotocol. CHRONIC STUDIES. Dogs had 201Tl and
9mTc-MIBI vasodilator stress imaging performed
n 2 successive weeks; week 1 with regadenoson
nd week 2 with adenosine. The week between
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1200essions. During the first session (Fig. 1A), each dog
eceived an intravenous injection of regadenoson (2.5
g/kg) over 30 s and then 201Tl (55.5  7.4 MBq)
0 s later. Dynamic planar imaging (DPI; 15 min)
ollowed the injection, along with timed arterial blood
ampling for determination of radiotracer clearance
inetics by use of a roller-pump (20 samples at 15
/sample, then 10 samples at 30 s/sample). Blood (0.5
l) was collected, weighed, and counted in a gamma-
ell-counter. Two hours later, the same regadenoson
asodilator stress protocol was repeated with injection
f 99mTc-MIBI (843.6  148 MBq).
For the second session (Fig. 1B), the dogs received
n intravenous infusion of adenosine at a rate of 280
g/kg/min over 4.5 min. An injection of 201Tl
59.2  3.7 MBq) was given 1.5 min into the
denosine infusion. Then DPI and blood withdraw-
ls, with use of the same protocol as with regadenoson,
ollowed the injection. Two hours later, the adenosine
tress protocol was repeated but with injection of
9mTc-MIBI (858.4 144.3 MBq). The blood clear-
nce half-time was calculated by the use of a logarith-
ic transform for both tracers with both vasodilators.
CUTE STUDIES. On week 3, open-chest studies
ere performed (Fig. 1C) after creation of a critical
CX stenosis. Regadenoson (2.5 g/kg) was in-
Dynamic Planar Im
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Figure 1. Experimental Protocols and Timelines
The protocol for closed-chest regadenoson studies performed on w
(B), and for an acute open-chest study performed on week 3 (C). H
99m 201Tc  technetium-99m; Tl  thallium-201.ected intravenously over 30 s, and 201Tl (51.8 3.7
Bq), 99mTc-MIBI (873.2  166.5 MBq), and
adiolabeled microspheres were injected simulta-
eously 10 s after the regadenoson bolus. To min-
mize redistribution, dogs were euthanized 15 min
fter tracer injection. Regional myocardial flow was
easured at rest and stress with radiolabeled micro-
pheres by the use of established methods (2). Hearts
ere excised and cast with dental molding material
Alginate, Type I, fast-set, Quala Dental Products,
DC Milford, Delaware) for ex vivo single-photon
mission computed tomography (SPECT) imaging,
voiding most of the confounding effects of attenua-
ion and scatter. Hearts were sliced (5 mm), and each
lice was divided into 8 radial pies. Segments under-
ent gamma-well-counting for the determination of
racer activity and microsphere flow.
emodynamics. Electrocardiogram, AoP, and coro-
ary flows were recorded 30 s before and after infusion
f the vasodilator (Sonolab, Sonometrics Inc., On-
ario, Canada). R-waves were used to segment the
ignals into individual cardiac cycles. Heart rate, sys-
olic and diastolic AoP, and peak LAD and LCX flow
ere determined every 10 s.
lanar imaging. Five-second images were acquired
or the first 30 s followed by 30-s images for the
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1201emaining 14.5 min for analyzing changes in myo-
ardial and background activity. Images were ac-
uired with a large field-of-view gamma-camera
Millennium VG, GE Healthcare, Milwaukee,
isconsin) by the use of a high-resolution, parallel-
ole collimator. Images (256  256 matrix) were
cquired without magnification in an anterior view
Figure 2. Hemodynamic Response in the Chronic Studies
Heart rate, systolic, and diastolic aortic pressure time-dependent ch
isotope: (A) 201Tl during regadenoson stress; (B) 201Tl during adeno
MIBI during adenosine stress. The dashed line indicates the radiotr
Table 1. Hemodynamic Effects
Radiotracer 201Tl
Stressor Adenosine
Peak values (% baseline)
Diastolic AoP 76.6 5.1*
Systolic AoP 84.9 3.8*
Heart rate 131.3 4.7*
2-min post-values (% baseline)
Diastolic AoP 81.9 4.5*†
Systolic AoP 89.7 3.3*†
Heart rate 124.3 4.5*†
End values (% baseline)
Diastolic AoP 97.5 2.4
Systolic AoP 97.7 2.9
Heart rate 103.1 4.7
Heart rate and systolic and diastolic AoP are shown for select time points after th
during the 2 min after radiotracer injection, and the value at 10 min after infu
groups. *p  0.05 versus baseline. †p  0.05 versus peak values.
AoP  aortic pressure; 99mTc  technetium-99m; 201Tl  thallium-201.with the adenosine response. The hemodynamic effect for each stressoy the use of appropriate energy windows for 201Tl
71  7.5% keV), and 99mTc-MIBI (140  7.5%
eV). Regions-of-interest were drawn over blood
ool, myocardium, liver, lung, and kidney. Time-
ctivity curves were generated for each organ, and
ctivity was expressed as percent-injected dose/pixel
%ID/pixel) by the use of an external point source
es (%baseline) after the stressor infusion (shaded box) for each
stress; (C) 99mTc-MIBI during regadenoson stress; and (D) 99mTc-
injection. The rapid effect of regadenoson is evident compared
99mTc-MIBI
egadenoson Adenosine Regadenoson
70.5 6.0* 75.5 2.6* 75.7 4.0*
81.7 5.3* 83.2 2.5* 85.1 2.1*
22.2 8.5* 123.3 7.3* 120.7 8.1*
77.5 5.0*† 80.8 2.1*† 80.1 4.1*†
87.7 3.9*† 86.5 2.2*† 89.2 2.4*†
13.5 8.9† 117.8 6.5* 116.1 7.0*†
90.2 4.8* 92.4 3.7* 89.4 1.3*
89.2 4.5* 93.6 3.1* 92.0 1.7*
00.2 6.4 97.0 3.3 101.1 5.7
ssor infusion. Shown are the peak alteration from baseline, the average change
of the stressor. There was no difference in the hemodynamic effects betweenang
sine
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1202f known activity. The myocardium-to-liver activity
nd myocardium-to-lung ratios, at 15 min for 201Tl
nd 99mTc-MIBI, were compared.
yocardial blood ﬂow. Myocardial segments were
eighed and counted within 24 h for determination of
01Tl and 99mTc activity in a gamma-scintillation-
ounter (Packard Instruments, Milford, Connecticut)
y the use of energy windows for 201Tl, 99mTc, and all
icrospheres (201Tl: 67 to 91 keV, 99mTc: 130 to 170
eV, 51Cr: 290 to 360 keV, 113Sn: 361 to 440 keV,
03Ru: 460 to 550 keV, 95Nb: 700 to 810 keV, 46Sc:
11 to 1,160 keV). Samples were recounted 1 week
fter radiotracer injection to determine microsphere
ow. Myocardial flow was calculated by the use of
reviously published methods, with correction for
adiotracer decay, spill-up, and spill-down (2). Re-
ional flow was expressed in ml/min/g, as well as a
ercent nonischemic and ischemic.
x vivo SPECT imaging. Ex vivo dual-isotope 201Tl
nd 99mTc-MIBI SPECT imaging was performed
y use of the same dual-head rotational gamma-
amera, collimators, and energy windows applied
or in vivo SPECT imaging. Images were acquired
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Figure 3. Clearance Half-Time and Biodistribution
The time-arterial blood activity curves for 201Tl and 99mTc-MIBI after
clearance half-times for 201Tl and 99mTc-MIBI with regadenoson and
for 99mTc-MIBI than for 201Tl with both stressors. (D) An example of
denoson infusion is shown. The images show where the regions-of-
the logarithm (%ID/pixel) for 201Tl and 99mTc-MIBI with both stresso
ent between stressors for 201Tl and 99mTc-MIBI (I and J, respectivelyy the use of a 360° circular-orbit, in a step-and- ohoot fashion (64  64 matrix; 5-mm slice thick-
ess). No attenuation or scatter correction was
equired. Images were reconstructed by the use of
ltered back-projection with ramp-filters. A
-dimensional low-pass filter (Butterworth, order-4
nd cutoff 0.35) was applied to post-reconstruction
ransverse SPECT slices, and images were reori-
nted into cardiac-specific axes.
The Yale-CQ-algorithm was used to quantify
he SPECT images (19,20). Circumferential count
rofiles were generated for a series of left ventricular
LV) short-axis images. Three anatomic slices were
ivided into 128 radial sectors. Defects were de-
ned as counts 80% of the maximum. 201Tl and
9mTc-MIBI integrated defect scores (%LV) were
alculated, providing an index of both the magni-
ude and extent of the perfusion abnormality.
tatistical analysis. Ischemic (IS) and nonischemic
NI) segments were defined by a coronary flow
eserve1.5 and2.5, respectively. On the basis of
his myocardial segmentation, IS/NI tracer and
ow ratios were calculated and compared. All values
re expressed as mean  SEM. Statistical differences
Adenosine
n=5 n=5
p<0.01
201TI
99m Tc-MIBI
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Time (min)
0
0 1 2 3 4 5 6 7 8 9 10
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1
201TI   (n=5)
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infusion of regadenoson (A) or adenosine (B) are shown. (C) The
nosine are shown. The clearance half-time is signiﬁcantly shorter
ynamic series of 99mTc-MIBI planar images, following a 30-s rega-
rest were drawn. The time-dependent biodistribution is shown as
to H). The biodistribution at 15 min after injection was no differ-
ntinued on next page.0
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1203racer between the regadenoson- and adenosine-
reated animals were assessed using a one-way
nalysis of variance. For conditions that demon-
trated a significant main effect, post-hoc analyses
ere performed with either a t test (comparison
etween 2 populations) or a z test (comparison with
baseline).
E S U L T S
hronic studies. HEMODYNAMICS. A 30-s bolus of
egadenoson and a 4.5-min infusion of adenosine
roduced similar hemodynamic effects (p  NS)
Table 1). Peak HR significantly increased (p 
.05), and peak systolic and diastolic AoP signifi-
antly decreased (p  0.05) relative to baseline
alues. These parameters were significantly (p 
.05) different than baseline 2 min after injection of
he radiotracers. These values tended to return to
Figure 3. Continued.aseline within 10 min (Fig. 2). The peak effect of legadenoson occurs 30 s after the bolus, whereas
he peak effect of adenosine occurs 1.5 to 2 min
fter beginning the infusion, corresponding to ra-
iotracer injection. The duration of the peak hemo-
ynamic effect was shorter for regadenoson than for
denosine, although sufficient to create differential
ptake of 201Tl and 99mTc-MIBI.
ADIOTRACER CLEARANCE AND BIODISTRIBU-
ION. The arterial blood clearance half-time was
ignificantly faster (p  0.01) for 99mTc-MIBI
regadenoson: 1.4  0.03 min; adenosine: 1.5 
.08 min) than for 201Tl (regadenoson: 2.5  0.16
in; adenosine: 2.7  0.04 min) (Figs. 3A to 3C).
There was no statistical difference in the biodis-
ribution of 201Tl or 99mTc-MIBI associated with
egadenoson and adenosine. However, 201Tl (rega-
enoson: 1.63  0.31; adenosine: 1.37  0.20) had
ignificantly greater (p  0.05) myocardium-to-
iver ratios compared with 99mTc-MIBI (regadeno-
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1204on: 0.56 0.06; adenosine: 0.60 0.06) at 15 min
fter injection. There was no difference in the
yocardium-to-lung ratio between 201Tl (regade-
oson: 2.84  0.64; adenosine: 2.36  0.47) and
9mTc-MIBI (regadenoson: 2.12  0.18; adenosine:
Figure 4. Hemodynamic Response in Acute Studies
The hemodynamic response to the 30-s regadenoson bolus
(shaded box) for the acute studies: heart rate (A), systolic and
diastolic aortic pressure response (B), and LAD and LCX coro-
nary ﬂow (C) responses. All values are %baseline. The dashed
line indicates the radiotracer injection. There was a 3-fold
increase in nonstenotic LAD ﬂow and no increase in LCX ﬂow.
LAD  left anterior descending; LCX  left circumﬂex artery..82 0.09) at 15 min after injection. The radiotracerptake during the initial 15 min after injection also
as expressed as a %ID/pixel (Figs. 3D to 3J).
cute studies. HEMODYNAMICS. In the acute stud-
es (n  7), the 30-s bolus of regadenoson caused a
early significant increase in HR (p  0.08) and a
ecrease (p  0.05) in both systolic and diastolic
oP during the 2-min post-radiotracer injection,
imilar to the chronic studies. The pressures re-
ained mildly reduced (10 mm Hg; p  0.05) at
0 min after regadenoson administration. The flow
n the stenotic LCX increased on average 6.7% (p
.05) over baseline, which is consistent with abla-
ion of reactive hyperemia. In the LAD, however,
he flow significantly increased (2.5- to 3-fold
aseline; p  0.001) during the 2 min after radio-
racer injection. The LAD flow returned to baseline
alues at 10 min after regadenoson infusion (Fig. 4).
YOCARDIAL MICROSPHERE BLOOD FLOW. Trans-
ural myocardial microsphere blood flow (Fig. 5) was
imilar between IS (0.86  0.24 ml/min/g) and NI
0.89  0.26 ml/min/g) territories at baseline. Regade-
oson caused 3.3-fold increase in myocardial blood
ow (MBF) in the NI territory (2.98 0.98 ml/min/g;
 0.05), whereas MBF in the ischemic territory was
nchanged (0.95  0.23 ml/min/g, p  NS).
YOCARDIAL RADIOTRACER ACTIVITY VERSUS
LOW. The deficit in relative myocardial uptake of
01Tl and 99mTc-MIBI in the stenotic region dur-
ng regadenoson vasodilator stress underestimated
he relative microsphere blood flow deficit. The
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Figure 5. Transmural Absolute Myocardial Blood Flow
Average microsphere ﬂows for ischemic and nonischemic
regions at rest and during vasodilator stress. The blood ﬂows
are comparable at rest in both regions. Flows during regadeno-
son vasodilator stress increased 3-fold in the nonischemic region
but remained unchanged in the ischemic region with a critical
stenosis.
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1205patial variation of radiotracer uptake and myocar-
ial microsphere flow is shown for a representative
yocardial short-axis slice (Fig. 6A). Relative 201Tl
ctivity approximated the flow deficit within the
schemic region better than 99mTc-MIBI activity.
igure 6B shows the relationship between absolute
yocardial flow and relative 201Tl and 99mTc-MIBI
etention for all segments of 1 dog. There was a
inear relationship between relative myocardial
01Tl activity and microsphere flow, even at the
igh flows achieved with regadenoson. However,
here was considerable “roll-off” of 99mTc-MIBI at
ows 1.5 times above resting flow (Fig. 6B). The
yocardial IS/NI ratio of both 201Tl (0.53  0.02)
nd 99mTc-MIBI (0.69 0.03) significantly under-
stimated (p  0.001) the true flow deficit (0.34 
.02). However, the underestimation associated
ith 201Tl activity was significantly (p 0.001) less
han that observed for 99mTc-MIBI (Fig. 6C).
X VIVO SPECT QUANTIFICATION. The differences in
elative regional 201Tl and 99mTc-MIBI uptake within
he stenotic territory during regadenoson stress, demon-
trated by gamma-well-counting, could also be visu-
lized on ex vivo SPECT imaging, under conditions
f minimal attenuation and scatter. Ex vivo images
learly showed the perfusion heterogeneity created
sing regadenoson in the presence of a critical stenosis
Fig. 7A). However, the perfusion defect appears
arger and more noticeable with 201Tl compared with
9mTc-MIBI, despite the lower count density. The
ntegrated perfusion defect score was significantly
Figure 7. SPECT Integrated Defect Size
(A) Series of 201Tl and 99mTc-MIBI ex vivo short-axis slices from a repre
tative dog are shown. With a critical stenosis, there were no marked p
fusion defects; however, the perfusion defects were visually smaller in
99mTc-MIBI images compared with 201Tl images. (B) The integrated def
magnitude calculated using the Yale-CQ-quantitative-program is showFigure 6. Perfusion Deﬁcit
(A) Circumferential proﬁle from a representative left ventricular
short-axis slice is shown. There was uniform ﬂow at rest and a
signiﬁcant heterogeneity of ﬂow with regadenoson as measured
by microspheres. (B) Tracer activity (%Ischemic) versus ﬂow is
shown. Regional myocardial 99mTc-MIBI activity plateaus at
greater ﬂows. (C) The ischemic/nonischemic ratio for ﬂow, 201Tl,
and 99mTc-MIBI is shown. Both radiotracers signiﬁcantly underes-
timate ﬂow heterogeneity. IS  ischemic; NI  nonischemic;sen-
er-
ect
n.%LV  percent left ventricular; other abbreviations as in Figure 1.
l
w
D
T
s
t
c
a
r
h
i
m
c
2
w
i
w
a
w
t
t
fl
t
T
t
b
o
(
v
d
s
i
M
f
h
v
a
q
n
s
v
c
O
9
g
i
a
d
a
p
h
r
fl
t
r
u
f
r
2
r
2
r
9
a
s
e
a
a
r
l
s
s
i
t
t
s
e
i
S
s
(
9
a
o
r
c
t
g
r
9
b
a
r
(
2
l
i
I
d
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 1 0 , 2 0 0 9
O C T O B E R 2 0 0 9 : 1 1 9 8 – 2 0 8
Mekkaoui et al.
Adenosine and Regadenoson Vasodilators
1206arger (p  0.05) with 201Tl (22  2.8 %LV) than
ith 99mTc-MIBI (17  1.7 %LV) (Fig. 7B).
I S C U S S I O N
he current study compared the effects of regadeno-
on and adenosine on systemic hemodynamics, radio-
racer biodistribution, and clearance kinetics in clini-
ally relevant canine models to define the optimal
pproach for MPI by the use of vasodilator stress. A
egadenoson bolus (2.5 g/kg) produced systemic
emodynamic effects similar to a 4.5-min adenosine
nfusion. Regadenoson created a 2.5- to 3-fold aug-
entation in microspheres flow. The HR, AoP, and
oronary flow remained altered during the critical
-min post-radiotracer injection. These effects on flow
ere comparable to those observed by Lieu et al. (18)
n human studies, in which they used a Doppler flow
ire measuring the coronary flow velocity in response to
400-g or 500-g bolus of regadenoson. These doses
ere greater than what was administered to the dogs in
he current study after body mass correction.
Although regadenoson and adenosine are known
o have differential effects on renal and splanchnic
ow (10), both vasodilators caused a similar biodis-
ribution and clearance of 201Tl and 99mTc-MIBI.
he use of DPI demonstrated a favorable biodis-
ribution of both radiotracers, which was compara-
le between the vasodilators. Unexpectedly, we
bserved a faster blood clearance of 99mTc-MIBI
1.5 min) compared with 201Tl (2.5 min) with both
asodilators. This finding suggests that a longer
uration of vasodilator stress, regardless of the
pecific vasodilator, might be more important after
njection of 201Tl than after injection of 99mTc-
IBI. However, 201Tl performed better as a per-
usion agent for the detection of relative flow
eterogeneity using regadenoson as defined by ex
ivo SPECT and well-counting techniques.
The injection of 201Tl or 99mTc-MIBI 10 s
fter the 30-s bolus of regadenoson provided high-
uality ex vivo SPECT images, demonstrating sig-
ificant heterogeneity of relative myocardial perfu-
ion in the presence of a critical stenosis. These ex
ivo images were acquired under ideal imaging
onditions with minimal attenuation and scatter.
n the basis of tissue counting, both 201Tl and
9mTc-MIBI underestimated the true MBF hetero-
eneity as measured using microspheres. This find-
ng is consistent with previous studies in which the
uthors evaluated 201Tl and 99mTc-MIBI MPI
uring adenosine stress (9) and other selective A2A
denosine agonists (21). We observed the expected
lateau of radiotracer uptake at higher flows, which pas been attributed to a diffusion limitation of
adiotracer uptake. In the case of 201Tl, some of the
ow underestimation may be attributed to differen-
ial washout of 201Tl from the normal and ischemic
egions, since the radiotracer distribution was eval-
ated at 15 min after radiotracer injection. There-
ore, there may have been a slight component of 201Tl
edistribution contributing to the observed plateau of
01Tl retention. Despite the potential for early 201Tl
edistribution, the more linear myocardial uptake of
01Tl relative to flow during vasodilator stress with
egadenoson suggests that 201Tl may be better than
9mTc-MIBI or other similar 99mTc-labeled perfusion
gents for use with vasodilator stress.
Although in this study a matched group of acute
tudies was not performed with adenosine, Glover
t al. (9) previously reported similar results using
denosine in an open-chest canine study. Glover et
l. (9) evaluated 201Tl and 99mTc-MIBI uptake
elative to microsphere flow in the presence of 2
evels of stenosis. Their creation of a “critical
tenosis” was designed to ablate reactive hyperemia,
imilar to our acute studies. The microsphere flows
n both studies demonstrated no increase in flow in
he stenotic territory and3.5-fold flow increase in
he remote territory in response to vasodilator
tress. Glover et al. (9) used planar imaging of
xcised LV slices from dogs euthanized 5 min after
njection of radiotracers compared with ex vivo
PECT imaging in our study. They demonstrated a
imilar underestimation of the true flow deficit
0.17  0.03) with both 201Tl (0.37  0.05) and
9mTc-MIBI (0.53  0.06) and that 201Tl provided
better estimation of the flow deficit (9), similar to
ur observation using regadenoson.
The recent ADVANCE (ADenoscan Versus
egAdenosoN Comparative Evaluation for Myo-
ardial Perfusion Imaging) phae 3 multicenter in-
ernational trial showed no difference between re-
adenoson and adenosine for determination of
eversible perfusion defects with 99mTc-MIBI or
9mTc-Tetrofosmin, although the chi-squares for
oth the adenosine-regadenoson and adenosine-
denosine comparisons were only 0.63 or 0.64,
espectively, suggesting only a fair concordance
14). On the basis of our experimental findings,
01Tl may offer a clinical advantage over the 99mTc-
abeled perfusion agents and improve test reproduc-
bility for determination of the extent of ischemia.
mportantly, the current finding regarding the bio-
istribution and ex vivo SPECT imaging would
redict that there should be no significant clini-
c
f
i
M
w
h
d
l
s
u
H
c
a
e
u
l
A
t
t
l
t
o
f
w
s
p
v
a
M
o
a
m
c
i
d
c
a
t
v
d

i
C
T
a
i
c
d
s
i
s
t
i
A
T
X
B
R
s
o
R
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 1 0 , 2 0 0 9
O C T O B E R 2 0 0 9 : 1 1 9 8 – 2 0 8
Mekkaoui et al.
Adenosine and Regadenoson Vasodilators
1207al difference between regadenoson and adenosine
or MPI.
Although this pre-clinical study provides important
nsight regarding regadenoson and adenosine stress
PI, these studies were performed during anesthesia,
hich could produce confounding effects on systemic
emodynamics. In clinical studies (13,14), the hemo-
ynamic changes associated with regadenoson were
ess and shorter-lasting than those observed in our
tudy. Our study was specifically performed with the
se of the volatile anesthetic halothane. Because
ickey et al. (22) found that there was no significant
hange in coronary flow reserve between conscious
nd halothane-anesthetized canines.
In addition, to minimize any potential adverse
ffect, the chronic studies were performed with the
se of a closed-chest preparation that required very
ight anesthesia with halothane and nitrous oxide.
lthough halothane is a mild cardiac depressant,
he effects are dose dependent (23,24). Therefore,
he light plane of anesthesia used should have had
ittle effect on cardiac output and the biodistribu-
ion of the radiotracers. Our hemodynamic results
n anesthetized dogs closely matched the result
rom previous studies on conscious dogs (11) and
ere within physiological ranges throughout the
tudy protocol. Glover et al. (9) used sodium
entobarbital anesthesia in their study and showed
ery similar hemodynamic responses to adenosine
nd similar kinetic behavior of 201Tl and 99mTc-
IBI during adenosine stress (9).
Our anesthetized preparation offers advantages
ver clinical studies or conscious preparations, en-J Nucl Med 1989;30:301–11. Coron Artery Dis 1ovement, which is a significant confounder in
linical studies with repeated imaging. The changes
n flow that we observed in our experimental model
uring vasodilator stress are concordant with a
linical study (25) in which the authors used rest
nd adenosine oxygen-15 water positron emission
omographic imaging in control subjects. Coronary
asodilator reserve (3.16  1.4) in control patients
uring adenosine stress was nearly identical to the
3.3-fold increase we obtained in the NI territory
n response to regadenoson vasodilator stress.
O N C L U S I O N S
he bolus administration of regadenoson produced
hyperemic response comparable to a standard
nfusion of adenosine. The biodistribution and
learance kinetics of both 201Tl and 99mTc-MIBI
uring regadenoson were similar to adenosine va-
odilation. Ex vivo perfusion images under the most
deal conditions permitted detection of a critical
tenosis, although 201Tl offered significant advan-
ages over 99mTc-MIBI for perfusion imaging dur-
ng regadenoson vasodilator stress.
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